Experimental cocktail targets Hard-to-Treat cancers
NCT ID NCT04840589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called ZEN003694, which blocks certain enzymes that help cancer grow, combined with two immunotherapy drugs (nivolumab and ipilimumab) that boost the immune system to attack cancer. The study includes 66 adults with advanced solid tumors, including a specific type of ovarian cancer. The main goals are to find the safest dose and see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZEN003694 (BET inhibitor) combined with nivolumab and ipilimumab
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) trial, so the main goal is just to find a safe dose. It is too soon to know if the combination will actually shrink tumors, and the trial is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-RESISTANT OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Montefiore Medical Center-Weiler Hospital
The Bronx, New York, 10461, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States